RAYMOND KIMBALL: Open Payments
NPI 1285668608 · ANDERSON, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$984 in 41 payments from 10 companies in 2025. Trend: 2023 $306 · 2024 $670 · 2025 $984
Food & beverage: $984
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 9 | $263 |
| Otsuka America Pharmaceutical, Inc. | 11 | $247 |
| Teva Pharmaceuticals USA, Inc. | 8 | $207 |
| Alkermes, Inc. | 3 | $69 |
| Neurocrine BioSciences, Inc. | 2 | $45 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $41 |
| Janssen Pharmaceuticals, Inc | 2 | $37 |
| Vanda Pharmaceuticals Inc. | 2 | $31 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Lundbeck LLC | 1 | $19 |
Products named: COBENFY, ABILIFY MAINTENA, UZEDY, AUSTEDO XR, ABILIFY ASIMTUFII, REXULTI, INGREZZA, CAPLYTA.
Industry payments across SC — which companies pay providers there.
